Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
about
Philadelphia positive acute lymphoblastic leukaemia of childhood.Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia.Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.Philadelphia chromosome-positive acute lymphoblastic leukemia.New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly.Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia.Management of Philadelphia chromosome-positive acute lymphoblastic leukemia.Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT.Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.SHP2 is required for BCR-ABL1-induced hematologic neoplasia.Successful treatment with interferon-alpha-2b and imatinib in an adult Japanese male with Philadelphia chromosome-positive acute lymphoblastic leukemia and minimal residual disease following allogeneic transplantation.Sustaining integrating imatinib and interferon-α into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic stem cell transplantation.
P2860
Q36228062-C6BCA2D7-7934-4FDE-BF5D-64EEDF45EF53Q36600241-93BECBF4-B32A-4A62-91FE-522DD3823863Q37152745-68443D95-3ED2-4B5B-9800-FC4EE2830940Q37613888-2392781D-FA74-4784-BE82-D18C82446761Q37836938-D5535496-C627-410F-9F51-568263CB465AQ37931235-86E0B5FF-B032-4AE3-B72C-53C04DEDB780Q38207017-22CFA715-DB51-4BCF-A34F-90708279BAF1Q38774759-56C62B0F-E07A-4C92-9D46-BC9D168E9D10Q40817830-F5A1D9F9-C293-4479-946C-DD6258AD185CQ41715958-151DA96E-11FD-471B-B8E3-2D7CA1825DEAQ46022670-A743730C-1620-41DF-97DE-DEC46AF33BC5Q46361900-1139E2FD-4FAD-48AA-A2A4-FA84CDA6EF4CQ46807799-75E90C94-7FA5-439B-9E8B-E4B612E79347Q50880138-B8E4FC4D-2328-45E3-AB9F-3BEA0B1915C4
P2860
Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Efficacy and safety of imatini ...... mphoblastic leukemia (Ph+ALL).
@en
Efficacy and safety of imatinib mesylate
@nl
type
label
Efficacy and safety of imatini ...... mphoblastic leukemia (Ph+ALL).
@en
Efficacy and safety of imatinib mesylate
@nl
prefLabel
Efficacy and safety of imatini ...... mphoblastic leukemia (Ph+ALL).
@en
Efficacy and safety of imatinib mesylate
@nl
P2093
P2860
P356
P1433
P1476
Efficacy and safety of imatini ...... mphoblastic leukemia (Ph+ALL).
@en
P2093
Binckebanck A
Gschaidmeier H
Scheuring U
Wassmann B
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403093
P577
2003-10-01T00:00:00Z